ASND has been in the news 353% more than usual
Sep 11, 2024, 10:31 PM
15.39%
What does ASND do
Ascendis Pharma A/S is a global biopharmaceutical company developing drug candidates for growth hormone deficiency, endocrinology, CNS disorders, infectious diseases, and diabetes. It operates through multiple subsidiaries in Germany and Denmark.
ASND has been in the news recently: Ascendis Pharma's YORVIPATH has been granted seven years of U.S. FDA Orphan Drug exclusivity for the treatment of hypoparathyroidism in adults, affecting approximately 70,000 to 90,000 patients. Meanwhile, XOMA Royalty Corporation, Bitdeer Technologies Group, and Endava are experiencing significant revenue and earnings growth, with projected annual earnings growth rates of 75.18%, 98.9%, and 35.8%, respectively.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.